Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced a strategic partnership with ANT Neuro, a global leader in precision brain mapping and neuronavigation technologies, to expand the capabilities of the NeuroStar® Advanced Therapy System with advanced image-guided navigation technology.

GlobeNewsWire • May 14, 2026

Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript

Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 5, 2026

Neuronetics Reports First Quarter 2026 Financial and Operating Results

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2026.

GlobeNewsWire • May 5, 2026

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics (STIM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.21 per share a year ago.

Zacks Investment Research • May 5, 2026

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.

GlobeNewsWire • Apr 29, 2026

Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that it plans to release first quarter 2026 financial and operating results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/3pztkve5 . To listen to the conference call on your telephone, participants may register for the call here . While it is not required, it is recommended you join 10 minutes prior to the event start. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. Investor Contact: Mike Vallie or Mark KlausnerICR [email protected] Media Contact: [email protected]

GlobeNewsWire • Apr 21, 2026

Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners

Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 States and Washington, D.C. Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 States and Washington, D.C.

GlobeNewsWire • Apr 13, 2026

Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business

Delivers Letter to STIM Board Outlining Potential 5-7x Upside for Shareholders Inherent in Sale of TMS and Standalone Clinic Business BLOOMFIELD HILLS, Mich., April 6, 2026 /PRNewswire/ -- Jorey Chernett, the largest independent shareholder of Neuronetics, Inc. (NASDAQ: STIM) (the "Company" or "Neuronetics") owning approximately 14.12% of outstanding shares, today delivered a letter to the STIM Board of Directors (the "Board") calling for the immediate initiation of a comprehensive review of strategic alternatives, including the potential sale of the Company's TMS business.

PRNewsWire • Apr 6, 2026

Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript

Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 17, 2026

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; proven medical device leader with more than 30 years of experience scaling commercial healthcare businesses MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2025.

GlobeNewsWire • Mar 17, 2026